Osteoarthritis Therapeutics Market Report 2025

This Osteoarthritis Therapeutics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The osteoarthritis therapeutics market size has grown strongly in recent years. It will grow from $8.17 billion in 2024 to $8.87 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to an aging population, advancements in drug delivery systems, increasing awareness and diagnosis, development of novel therapies, and rising obesity rates.

The osteoarthritis therapeutics market size is expected to see strong growth in the next few years. It will grow to $12.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rising obesity rates, advancements in treatment modalities, increasing awareness and diagnosis, development of disease-modifying osteoarthritis drugs (DMOADs), and government and private funding for research. Major trends in the forecast period include increasing focus on personalized medicine, the emergence of regenerative therapies, the expansion of pain management options, government and regulatory support, and rising demand in emerging markets.

The increase in sports injuries is expected to drive the growth of the osteoarthritis therapeutics market in the future. A sports injury refers to any damage or harm sustained during athletic activities, ranging from mild to severe, and affecting various parts of the body. The rise in sports injuries is primarily due to growing participation in sports and the increasing intensity and competitiveness of these activities. Osteoarthritis therapeutics are used to manage pain, reduce inflammation, and improve joint function in athletes experiencing joint degeneration from such injuries. For example, in 2022, the National Safety Council, a US-based nonprofit organization focused on health and safety, reported a 12% increase in sports and recreational injuries. As a result, the rising number of sports injuries is fueling the growth of the osteoarthritis therapeutics market.

Leading companies in the osteoarthritis therapeutics market are concentrating on developing innovative solutions, such as advancements in tissue regeneration for osteoarthritis. Tissue regeneration in osteoarthritis involves repairing or replacing damaged cartilage and joint tissues to restore function and alleviate pain. For instance, in May 2023, the Advanced Research Projects Agency for Health (ARPA-H), a US-based government agency, launched the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program. This program aims to create cutting-edge injectable therapies that stimulate cartilage repair by utilizing biological pathways similar to those active during embryonic development. A key aspect of NITRO is its collaborative, multimodal approach among research teams and the use of advanced testing techniques, such as "joint-on-a-chip" platforms that replicate joint environments. This initiative seeks to develop regenerative solutions that address the underlying causes of osteoarthritis, offering more effective long-term treatments.

In April 2022, Juniper Biologics Pte Ltd, a pharmaceutical company based in Singapore, acquired the licensing rights for TG-C LD (TissueGene-C low dose) from Kolon Life Science for $600 million. This acquisition positions Juniper Biologics as a leader in cell-mediated gene therapies for knee osteoarthritis, addressing a significant unmet medical need affecting around 300 million patients in the Asia Pacific, Middle East, and Africa regions. Kolon Life Science Inc., based in South Korea, specializes in osteoarthritis therapeutics.

Major companies operating in the osteoarthritis therapeutics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Zimmer Biomet Holdings Inc., Horizon Therapeutics plc, Taisho Pharmaceutical Co. Ltd., Ferring Pharmaceuticals, Galapagos NV, Bioventus LLC, Flexion Therapeutics Inc., Anika Therapeutics Inc., Seikagaku Corporation, Samumed LLC, Orthogen AG, Kolon Life Science Inc.

North America was the largest region in the osteoarthritis therapeutics market in 2023. The regions covered in the osteoarthritis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteoarthritis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Osteoarthritis therapeutics encompass a range of medical treatments and interventions aimed at managing and alleviating the symptoms of osteoarthritis, a degenerative joint disease marked by the deterioration of cartilage and underlying bone. These treatments include medications, physical therapies, lifestyle changes, and, in some cases, surgical procedures. The main objectives of osteoarthritis therapeutics are to reduce pain, enhance joint function, and improve the quality of life for those affected by the condition.

Key drug types for osteoarthritis management include viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, corticosteroids, and others. Viscosupplementation agents are injected directly into the joint to provide lubrication and cushioning, which helps relieve pain and improve mobility. The condition can affect various joints, such as the knee, hip, and hand, and treatments can be administered through different routes, including parenteral, topical, and oral. Sales channels for these therapeutics include prescription and over-the-counter drugs, with end-users ranging from hospital pharmacies to retail pharmacies and other outlets.

The osteoarthritis therapeutics market research report is one of a series of new reports that provides osteoarthritis therapeutics market statistics, including osteoarthritis therapeutics industry global market size, regional shares, competitors with a osteoarthritis therapeutics market share, detailed osteoarthritis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the osteoarthritis therapeutics industry. This osteoarthritis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoarthritis therapeutics market consists of revenues earned by entities by providing services such as exercises and therapies, diagnostic services, and pain management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoarthritis therapeutics market also includes sales of pain relievers, corticosteroids, hyaluronic acid injections, and assistive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.